Physicians' Academy for Cardiovascular Education

ACS

Stopping with aspirin after 3 months DAPT is safe in a wide range of patients

3' education - Apr. 2, 2020 - Prof. Freek Verheugt, MD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Hs-troponin measured 30 min after admission to diagnose MI

5' education - Oct. 24, 2019 - Paris, France - Camilla Bang, MD

Sex-related differences in ACS patients

5' education - Oct. 15, 2019 - Paris, France - Sanne Peters, PhD

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Reduced long-term CV death and MI with complete multivessel revascularization in STEMI

3' education - Sep. 25, 2019 - Paris, France - Prof. Shamir Mehta

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

No beneficial effects of oxygen use in subjects with a heart attack

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Ralph Stewart, New Zealand

A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge

3' education - Sep. 3, 2019 - Prof. Derek Chew

Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients

3' education - Sep. 3, 2019 - Danny Claassens

Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results

3' education - Sep. 1, 2019 - Paris, France - Prof. Stefanie Schüpke

Major benefits with implementation of rapid rule-out pathway for MI

3' education - Sep. 1, 2019 - Prof. Nicholas Mills

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Treatment of patients on oral anticoagulation who present with ACS

10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

No added value of monitoring platelet function after ACS

3' education - Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany
##SCROLLER_ITEMS_FULL_TITLE##

No indication for difference in efficacy between potent platelet inhibitors after PCI

3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Evolving hypotheses on the mechanisms underlying ACS

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

10' education - Sep. 29, 2015

P2Y12i monotherapy reduces net adverse clinical events in ACS patients undergoing PCI with DES

News - Apr. 9, 2020

ACC 2020 Ticagrelor monotherapy after 3-months DAPT reduces net adverse clinical events compared with continued DAPT in ACS patients who underwent PCI with drug-eluting stents (DES).

P2Y12i monotherapy after 3 months DAPT reduces bleeding after complex PCI

News - Apr. 7, 2020

ACC 2020 After an initial 3 months of DAPT, ticagrelor monotherapy after complex PCI lowered bleeding without increasing risk of ischemic events compared to continued use of DAPT.

Stopping with aspirin after 3 months DAPT is safe in a wide range of patients

3' education - Apr. 2, 2020 - Prof. Freek Verheugt, MD
Prof. Verheugt discusses the results of prespecified analyses of the TWILIGHT trial, in those with diabetes and those with complex PCI (the TWILIGHT-COMPLEX study).

ACC 2020 Prof. Verheugt discusses the results of prespecified analyses of the TWILIGHT trial, in those with diabetes and those with complex PCI (the TWILIGHT-COMPLEX study).

Genotype-guided post-PCI antiplatelet therapy just missed significance in reducing ischemic events

News - Mar. 29, 2020

ACC 2020 The TAILOR-PCI trial showed that genotype-guided antiplatelet therapy reduced ischemic events by 34% in patients who underwent PCI compared to conventional therapy.

No association between HDL particle concentration and MACE after ACS

Salahuddin T, et al.

Literature - Feb. 10, 2020 - Am Heart J 2019

An analysis of data of the dal-OUTCOMES trial shows that concentration of HDL particles is not associated with risk of MACE in patients after ACS.

ACS patients show less dense, calcified plaque than ACS-free controls on clinically indicated CCTA

Literature - Jan. 29, 2020 - Van Rosendael AR et al., - JAMA Cardiol. 2020

The ICONIC study provides support for the hypothesis that higher-density calcified plaques are more stable, as patients who had ACS had lower high-density plaque volume than those without an event.

Associations of outpatient use of P2Y12 inhibitors with MACE in ACS patients after PCI

Literature - Jan. 28, 2020 - Turgeon RD et al., - JAMA Intern Med. 2020.

This observational study of ACS patients after PCI showed that ticagrelor was not associated with lower MACE compared to clopidogrel, but was associated with more major bleeding and dyspnea.

Pre-PCI P2Y12 inhibitor administration and stent-induced endothelial dysfunction and inflammation in ACS

Literature - Jan. 8, 2020 - Schnorbus B et al., - Eur Heart J. 2020

Patients with ACS who received prasugrel before PCI, showed less endothelial dysfunction and platelet aggregation, while those on clopidogrel and ticagrelor did not, nor did treatment after PCI.

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD
Prof. Ray gives a presentation on the rationale, design and CV outcomes of the BETonMACE trial, in which the BET inhibitor apabetalone was evaluated compared to placebo in high-risk patients.

Prof. Ray gives a presentation on the rationale, design and CV outcomes of the BETonMACE trial, in which the BET inhibitor apabetalone was evaluated compared to placebo in high-risk patients.

Oral load of colchicine prior to PCI prevents a rise of inflammatory biomarkers in acute injury

News - Nov. 18, 2019

AHA 2019 Pre-procedural administration of colchicine vs. placebo did not reduce PCI-related myocardial injury or MACE at 30 days, but attenuated increase in IL-6 and hsCRP at 24 hours post-PCI.

Identification of parameters associated with plaque erosion in STEMI and NSTE-ACS

Literature - Oct. 30, 2019 - Yamamoto E et al., - J Am Heart Assoc. 2019

Exploratory analysis identifies predictors of plaque erosion in patients with ACS who underwent OCT imaging. A combination of non-traditional risk factors can increase the probability of erosion to up to 73%.

P2Y12i monotherapy reduces ischemic outcomes in patients undergoing multivessel PCI

Literature - Oct. 28, 2019 - Takahashi K, et al. - J Am Coll Cardiol 2019

A post-hoc analysis of the GLOBAL LEADERS trial in patient undergoing multivessel PCI showed that ticagrelor monotherapy reduced all-cause death or MI, without any difference in bleeding compared to standard DAPT regimen.